Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

Running, not enrolling

Conditions studied: Prurigo Nodularis

In brief

This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of PN. In addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated PN patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for PN.

Key facts

Study ID

NCT05991323

Run by

Sanofi

People needed

100

Starts

2023-12-12

Expected to finish

2026-09-22

Last updated by the study team

2025-09-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged 18 years or older at the time of informed consent.
• Physician decision to treat the patient with dupilumab for prurigo nodularis (according to the country-specific prescribing information) made prior to and independently of the patient's participation in the study.
• Patients able to understand and complete study-related questionnaires.
• Patients provide voluntary informed consent to participate in the study before inclusion in the study.

You may not qualify if…

• Patients who have a contraindication to dupilumab according to the country-specific prescribing information label.
• Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from completing the schedule of visits and assessments.
• Patients currently participating in any interventional clinical trial.
• Prior use of dupilumab within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day.

Where it is running

• Medical Dermatology Specialists Site Number : 8400005 — Phoenix, Arizona, United States
• Saguaro Dermatology Associates, LLC - Probity - PPDS- Site Number : 8400024 — Phoenix, Arizona, United States
• Center for Dermatology Clinical Research- Site Number : 8400002 — Fremont, California, United States
• Halcyon Dermatology- Site Number : 8400023 — Laguna Hills, California, United States
• Mission Dermatology - Rancho Santa Margarita- Site Number : 8400015 — Rancho Santa Margarita, California, United States
• Golden State Dermatology- Site Number : 8400014 — Walnut Creek, California, United States
• Total Vein And Skin, LLC- Site Number : 8400019 — Boynton Beach, Florida, United States
• GSI Clinical Research- Site Number : 8400017 — Margate, Florida, United States
• Allergy Center at Brookstone Research - Centricity Research - PPDS- Site Number : 8400025 — Columbus, Georgia, United States
• Dawes Fretzin Clinical Research Group-7910 N Shadeland Ave- Site Number : 8400003 — Indianapolis, Indiana, United States
• Oakland Hills Dermatology - 3400 Auburn Rd- Site Number : 8400007 — Auburn Hills, Michigan, United States
• Derm Institute of Western Michigan- Site Number : 8400034 — Caledonia, Michigan, United States
• Dermatology Associates Western Michigan- Site Number : 8400033 — Grand Rapids, Michigan, United States
• U.S. Dermatology Partners Lee's Summit- Site Number : 8400016 — Lee's Summit, Missouri, United States
• University of Nebraska - Lauritzen Outpatient Center- Site Number : 8400029 — Omaha, Nebraska, United States
• Vivida Dermatology - Flamingo- Site Number : 8400013 — Las Vegas, Nevada, United States
• Las Vegas Dermatology- Site Number : 8400027 — Las Vegas, Nevada, United States
• Duke Dermatology Clinic- Site Number : 8400026 — Durham, North Carolina, United States
• Medical University of South Carolina (MUSC) - PPDS- Site Number : 8400001 — Charleston, South Carolina, United States
• North Texas Center for Clinical Research- Site Number : 8400012 — Frisco, Texas, United States
• U.S. Dermatology Partners Longview- Site Number : 8400032 — Longview, Texas, United States
• Texas Tech University Health Sciences Center-125 W Hague Rd- Site Number : 8400010 — Lubbock, Texas, United States
• West Virginia Research Institute- Site Number : 8400030 — Morgantown, West Virginia, United States
• Investigational Site Number : 1240009 — Calgary, Alberta, Canada
• Investigational Site Number : 1240007 — Edmonton, Alberta, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.